Journal of Bone and Mineral Metabolism

, Volume 25, Issue 2, pp 105–113 | Cite as

Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women

  • Ellewellyn G. Pasion
  • Shanmugam K. Sivananthan
  • Annie Wai-Chee Kung
  • Sung-Hsiung Chen
  • Yen-Jen Chen
  • Roberto Mirasol
  • Boon Keng Tay
  • Ghazanfar Ali Shah
  • Mansoor Ali Khan
  • Frances Tam
  • Belinda J. Hall
  • Daniel Thiebaud
ORIGINAL ARTICLE

Abstract

We evaluated adherence with raloxifene therapy compared with daily bisphosphonate in Asian postmenopausal women at increased risk of osteoporotic fractures. In this 12-month observational study conducted in Asia (Hong Kong, Malaysia, Pakistan, Philippines, Singapore, Taiwan), 984 postmenopausal women (aged 55 years or older) were treated with raloxifene 60 mg/day (n = 707; 72%) or daily bisphosphonate (alendronate 10 mg/day; n = 206; 21%, or risedronate 5 mg/day; n = 71; 7%) during their normal course of care. Patients were assessed at baseline, 6, and 12 months. Baseline characteristics (including age, race, education, menopausal status, and baseline fractures) were comparable between the raloxifene and bisphosphonate groups. More women on raloxifene completed the study compared with those on bisphosphonate (50.2% versus 37.5%; P < 0.001). Patients also took raloxifene for a longer period than bisphosphonate (median, 356 versus 348 days; P = 0.011). Compared with those taking bisphosphonate, significantly fewer patients taking raloxifene discontinued the study because of stopping treatment (5.7% versus 10.1%, P = 0.017) or changing treatment (2.8% versus 9.7%, P < 0.001). Inconvenient dosing was reported as a primary reason for discontinuation due to stopping or changing treatment in 19 (6.9%) bisphosphonate patients compared with 0 raloxifene patients. The percentage of patients who had consumed 80% or more of their study medication was similar for raloxifene patients (48–56 weeks; 95.2%) and bisphosphonate patients (48–56 weeks; 93.3%). More raloxifene patients responded that they were satisfied with their medication than bisphosphonate patients at 48–56 weeks (P = 0.002). We concluded that Asian postmenopausal women at increased risk of osteoporotic fractures showed a greater propensity to remain on raloxifene compared with bisphosphonate. The women on raloxifene exhibited lower discontinuation rates and higher treatment satisfaction.

Key words

raloxifene osteoporosis adherence bisphosphonate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stepan, JJ, Alenfield, F, Boivin, G, Feyen, JHM, Lakatos, P 2003Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosisEndocr Regul37227240Google Scholar
  2. 2.
    Baker, VL, Ulrich, U 1999Estrogen replacement and alternatives for the prevention and treatment of osteoporosisCurr Probl Obstet Gynecol Fertil2280119Google Scholar
  3. 3.
    Miller, NH 1997Compliance with treatment regimens in chronic asymptomatic diseasesAm J Med1024349PubMedCrossRefGoogle Scholar
  4. 4.
    Osterberg, L, Blaschke, T 2005Adherence to medicationN Engl J Med353487497PubMedCrossRefGoogle Scholar
  5. 5.
    Solomon, DH, Avorn, J, Katz, JN, Finkelstein, JS, Arnold, M, Polinski, JM, Brookhart, MA 2005Compliance with osteoporosis medicationsArch Intern Med16524142419PubMedCrossRefGoogle Scholar
  6. 6.
    Fawcett, J 1995Compliance: definitions and key issuesJ Clin Psychiatry5648PubMedGoogle Scholar
  7. 7.
    Melnikow, J, Kiefe, C 1994Patient compliance and medical researchJ Gen Intern Med996105PubMedGoogle Scholar
  8. 8.
    Peck, CL, King, NJ 1985Compliance and the doctor-patient relationshipDrugs307884PubMedGoogle Scholar
  9. 9.
    Black, DM, Cummings, SR, Karpf, DB, Cauley, JA, Thompson, DE, Nevitt, MC, Bauer, DC, Genant, HK, Haskell, WL, Marcus, R, Ott, SM, Torner, JC, Quandt, SA, Reiss, TF, Ensrud, KE 1996Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet34815351541PubMedCrossRefGoogle Scholar
  10. 10.
    Cummings, SR, Black, DM, Thompson, DE, Applegate, WB, Barrett-Connor, E, Musliner, TA, Palermo, L, Prineas, R, Rubin, SM, Scott, JC, Vogt, T, Wallace, R, Yates, AJ, LaCroix, AZ 1998Effect of alendronate on risk fracture in women with low bone density but without vertebral fracturesJAMA28020772082PubMedCrossRefGoogle Scholar
  11. 11.
    Liberman, UA, Weiss, SR, Bröll, J, Minne, HW, Quan, H, Bell, NH, Rodriguezportales, J, Downs, RW, Dequeker, J, Favus, M, Seeman, E, Recker, RR, Capizzi, T, Santora, AC, Lombardi, A, Shah, RV, Hirsch, LJ, Karpf, DB 1995Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosisN Engl J Med33314371443PubMedCrossRefGoogle Scholar
  12. 12.
    Chesnut, CH,III, McClung, MR, Ensrud, KE, Bell, NH, Genant, HK, Harris, ST, Singer, FR, Stock, JL, Yood, RA, Delmas, PD, Kher, U, Pryortillotson, S, Santora, AC 1995Alendronate treatment of the postmenopausal osteoporosis woman: effect of multiple dosages on bone mass and bone remodelingAm J Med99144152PubMedCrossRefGoogle Scholar
  13. 13.
    Ettinger, B, Pressman, A, Schein, J 1998Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions and discontinuationJ Manag Care Pharm4488492Google Scholar
  14. 14.
    Boccuzzi, SJ, Foltz, SH, Omar, MA 2005Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonatesOsteoporos Int16S3OC10CrossRefGoogle Scholar
  15. 15.
    Delmas, PD, Bjarnason, NH, Mitlak, BH, Ravoux, AC, Shah, AS, Huster, WJ, Draper, M, Christiansen, C 1997Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal womenN Engl J Med33716411647PubMedCrossRefGoogle Scholar
  16. 16.
    Ettinger, B, Black, DM, Mitlak, BH, Knickerbocker, RK, Nickelsen, T, Genant, HK, Christiansen, C, Delmas, PD, Zanchetta, JR, Stakkestad, J, Gluer, CC, Krueger, K, Cohen, FJ, Eckert, S, Ensrud, KE, Avioli, LV, Lips, P, Cummings, SR 1999Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifeneJAMA282637645PubMedCrossRefGoogle Scholar
  17. 17.
    Walsh, BW, Kuller, LH, Wild, RA, Paul, S, Farmer, M, Lawrence, JB, Shah, AS, Anderson, PW, Rifkind, BM, Rossouw, JE 1998Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal womenJAMA27914451451PubMedCrossRefGoogle Scholar
  18. 18.
    Davies, GC, Huster, WJ, Shen, W, Mitlak, B, Plouffe, L,Jr, Shah, A, Cohen, FJ 1999Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal womenMenopause6188195PubMedGoogle Scholar
  19. 19.
    Cummings, SR, Eckert, S, Krueger, KA, Grady, D, Powles, TJ, Cauley, JA, Norton, L, Nickelsen, T, Bjarnason, NH, Morrow, M, Lippman, ME, Black, D, Glusman, JE, Costa, A, Jordan, VC 1999The effect of raloxifene on risk of breast cancer in postmenopausal womenJAMA28121892197PubMedCrossRefGoogle Scholar
  20. 20.
    Davies, GC, Huster, WJ, Lu, Y, Plouffe, L,Jr, Lakshmanan, M 1999Adverse events reported by postmenopausal women in controlled trials with raloxifeneObstet Gynecol93558565PubMedCrossRefGoogle Scholar
  21. 21.
    Turbí, C, Herrero-Beaumont, G, Acebes, JC, Turrijos, A, Grana, J, Miguelez, R, Sacristan, JA, Marin, F 2004Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational studyClin Ther26245256PubMedCrossRefGoogle Scholar
  22. 22.
    Zanchetta, JR, Hakim, C, Lombas, C 2004Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosisCurr Ther Res65470480CrossRefGoogle Scholar
  23. 23.
    Tosteson, ANA, Grove, MR, Hammond, CS, Moncur, MM, Ray, GT, Hebert, GM, Pressman, AR, Ettinger, B 2003Early discontinuation of treatment for osteoporosisAm J Med115209216PubMedCrossRefGoogle Scholar
  24. 24.
    Haynes, RB, Sackett, DL, Gibson, ES, Taylor, DW, Hackett, BC, Roberts, RS, Johnson, AL 1976Improvement of medication compliance in uncontrolled hypertensionLancet112651268PubMedCrossRefGoogle Scholar
  25. 25.
    Lips, P, van Schoor, NM 2005Quality of life in patients with osteoporosisOsteoporos Int16447455PubMedCrossRefGoogle Scholar
  26. 26.
    Recker R, Kendler D, Recknor C, Rooney T, Lewiecki EM, Utian WH, Cauley J, Lorraine J, Qu Y, Kulkarni PM, Plouffe L, Stock J (2005) Effects of raloxifene or alendronate on fracture risk reduction: results from the EVA (Evista®/Alendronate Comparison) Trial. Presented at the American Society for Bone and Mineral Research annual meeting, September 23-27, 2005, Nashville, TN (presentation number F425)Google Scholar
  27. 27.
    Nakamura, T, Liu, JL, Morii, H, Huang, QR, Zhu, HM, Qu, Y, Hamaya, E, Thiebaud, D 2006Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosisJ Bone Miner Metab24414418PubMedCrossRefGoogle Scholar
  28. 28.
    Cramer, JA, Amonkar, MM, Hebborn, A, Altman, R 2005Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosisCurr Med Res Opin2114531460PubMedCrossRefGoogle Scholar
  29. 29.
    Weycker, D, Macarios, D, Oster, G 2005Adherence with weekly versus daily bisphosphonate therapy among women with postmenopausal osteoporosisJ Bone Miner Res20S280281Google Scholar
  30. 30.
    McCombs, JS, Cody, M, Besinque, K, Borok, G, Ershoff, D, Groshen, S, Hay, J, Johnson, KA, Nichol, MB, Nye, MT 1995Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser Permanente/USC Patient Consultation StudyClin Ther1711881206PubMedCrossRefGoogle Scholar
  31. 31.
    Melnikow, J, Kiefe, C 1994Patient compliance and medical research: issues in methodologyJ Gen Intern Med996105PubMedGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2007

Authors and Affiliations

  • Ellewellyn G. Pasion
    • 1
  • Shanmugam K. Sivananthan
    • 2
  • Annie Wai-Chee Kung
    • 3
  • Sung-Hsiung Chen
    • 4
  • Yen-Jen Chen
    • 5
  • Roberto Mirasol
    • 6
  • Boon Keng Tay
    • 7
  • Ghazanfar Ali Shah
    • 8
  • Mansoor Ali Khan
    • 9
  • Frances Tam
    • 10
  • Belinda J. Hall
    • 11
  • Daniel Thiebaud
    • 12
  1. 1.University of the PhilippinesPhilippine General HospitalPhilippines
  2. 2.Hospital FatimahPerakMalaysia
  3. 3.The University of Hong KongQueen Mary HospitalHong Kong
  4. 4.Chang Gung Memorial HospitalKaohsiungTaiwan
  5. 5.Veterans General HospitalTaichungTaiwan
  6. 6.St. Luke's Medical CentreQuezon CityPhilippines
  7. 7.Singapore General HospitalSingapore
  8. 8.Doctor's HospitalLahorePakistan
  9. 9.Mideast Medical CentreKarachiPakistan
  10. 10.Eli Lilly CanadaTorontoCanada
  11. 11.Eli Lilly AustraliaSydneyAustralia
  12. 12.Eli Lilly Australia Pty LimitedNSWAustralia

Personalised recommendations